Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 07 tags : Therapy save search
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
Published: 2021-06-07 (Crawled : 23:00) - globenewswire.com
HOOK | $0.7649 0.32% 0.91% 0
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: -20.15%
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.03%
H: 0.25%
C: 0.1%
phase 1 therapy cancer phase 3 phase 2 t-cell
CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
Published: 2021-06-07 (Crawled : 16:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
|
| O: 0.31%
H: 1.24%
C: 0.27%
treatment potential therapy leukemia
FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy
Published: 2021-06-07 (Crawled : 14:00) - biospace.com/
MDT | $79.19 0.14% -0.57% 5.1M
|
Health Technology
|
| O: 0.44%
H: 0.6%
C: -0.35%
fda therapy fda approval approval
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 0.02%
H: 0.19%
C: -0.7%
KRBP | $2.5 8.7% -90.21% 830
|
Health Technology
|
| O: 2.59%
H: 9.09%
C: 6.9%
expansion therapy chmp
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
VERU | $1.42 22.41% 18.31% 6.9M
|
Health Technology
|
| O: 0.92%
H: 5.56%
C: 1.82%
phase 2 positive therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
BYSI | $1.8 -2.7% -2.21% 55K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
BYSI | $1.8 -2.7% -2.21% 55K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
APVO 3 d | $0.77 8.07% 6.25% 210K
|
Health Technology
|
| O: 0.04%
H: 1.25%
C: -1.94%
therapy antibody
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
UMAC | $1.55 0.65% 12.9% 0
|
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.